Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population.
APRI
FIB-4
FIB-5
non-alcoholic fatty liver disease
significant fibrosis
Journal
BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
02
2019
revised:
17
04
2019
accepted:
23
04
2019
entrez:
6
7
2019
pubmed:
6
7
2019
medline:
6
7
2019
Statut:
epublish
Résumé
Non-invasive assessment of fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is challenging, especially in resource-limited settings. MR or transient elastography and many patented serum scores are costly and not widely available. There are limited data on accuracy of serum-based fibrosis scores in urban slum-dwelling population, which is a unique group due to its dietary habits and socioeconomic environment. We did this study to compare the accuracy of serum-based fibrosis scores to rule out significant fibrosis (SF) in this population. Histological and clinical data of 100 consecutive urban slum-dwelling patients with NAFLD were analysed. Institutional ethics committee permission was taken. Aspartate transaminase (AST) to platelet ratio index (APRI), fibrosis-4 index (FIB-4) and FIB-5 scores were compared among those with non-significant fibrosis (METAVIR; F0 to F1; n=73) and SF (METAVIR; F2 to F4; n=27). AST (IU/mL) (68.3±45.2 vs 23.9±10.9; p<0.0001), alanine transaminase (IU/mL) (76.4±36.8 vs 27.9±11.4; p<0.0001), FIB-4 (2.40±2.13 vs 0.85±0.52; p<0.0001) and APRI (1.18±0.92 vs 0.25±0.16; p<0.0001) were higher and platelets (100 000/mm APRI but not FIB-5 or FIB-4 is accurate in ruling out SF in patients with NAFLD in an urban slum-dwelling population.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Non-invasive assessment of fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is challenging, especially in resource-limited settings. MR or transient elastography and many patented serum scores are costly and not widely available. There are limited data on accuracy of serum-based fibrosis scores in urban slum-dwelling population, which is a unique group due to its dietary habits and socioeconomic environment. We did this study to compare the accuracy of serum-based fibrosis scores to rule out significant fibrosis (SF) in this population.
METHODS
METHODS
Histological and clinical data of 100 consecutive urban slum-dwelling patients with NAFLD were analysed. Institutional ethics committee permission was taken. Aspartate transaminase (AST) to platelet ratio index (APRI), fibrosis-4 index (FIB-4) and FIB-5 scores were compared among those with non-significant fibrosis (METAVIR; F0 to F1; n=73) and SF (METAVIR; F2 to F4; n=27).
RESULTS
RESULTS
AST (IU/mL) (68.3±45.2 vs 23.9±10.9; p<0.0001), alanine transaminase (IU/mL) (76.4±36.8 vs 27.9±11.4; p<0.0001), FIB-4 (2.40±2.13 vs 0.85±0.52; p<0.0001) and APRI (1.18±0.92 vs 0.25±0.16; p<0.0001) were higher and platelets (100 000/mm
CONCLUSIONS
CONCLUSIONS
APRI but not FIB-5 or FIB-4 is accurate in ruling out SF in patients with NAFLD in an urban slum-dwelling population.
Identifiants
pubmed: 31275584
doi: 10.1136/bmjgast-2019-000288
pii: bmjgast-2019-000288
pmc: PMC6577364
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000288Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Am J Gastroenterol. 1999 Sep;94(9):2467-74
pubmed: 10484010
N Engl J Med. 2001 Feb 15;344(7):495-500
pubmed: 11172192
Am J Gastroenterol. 2002 Oct;97(10):2614-8
pubmed: 12385448
Hepatology. 2003 May;37(5):1202-19
pubmed: 12717402
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2003 Dec;38(6):1449-57
pubmed: 14647056
Br J Clin Pharmacol. 2004 Feb;57(2):199-208
pubmed: 14748819
Gut. 2006 Mar;55(3):310-2
pubmed: 16474104
Hepatol Res. 2006 Mar;34(3):163-9
pubmed: 16478676
BMC Gastroenterol. 2006 Feb 14;6:6
pubmed: 16503961
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
J Gastroenterol Hepatol. 2007 Jun;22(6):788-93
pubmed: 17565631
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Ann Hepatol. 2007 Jul-Sep;6(3):161-3
pubmed: 17786142
Hepatology. 2008 Feb;47(2):455-60
pubmed: 18038452
Diabetes Res Clin Pract. 2009 Apr;84(1):84-91
pubmed: 19168251
Transplant Proc. 2009 Mar;41(2):679-81
pubmed: 19328955
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12
pubmed: 19523535
Hepatology. 2010 May;51(5):1593-602
pubmed: 20222092
Gut. 2010 Sep;59(9):1265-9
pubmed: 20801772
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
BMC Gastroenterol. 2012 Jan 05;12:2
pubmed: 22221544
Indian J Endocrinol Metab. 2012 Jan;16(1):44-55
pubmed: 22276252
Ann Hepatol. 2012 Nov-Dec;11(6):855-61
pubmed: 23109448
Medicine (Baltimore). 2012 Nov;91(6):319-27
pubmed: 23117851
Indian J Matern Child Health. 2012 Jun;14(2):1-13
pubmed: 23400755
Indian J Med Res. 2015 Aug;142(2):139-50
pubmed: 26354211
Hepatol Res. 2016 Aug;46(9):862-70
pubmed: 26763834
Indian J Public Health. 2016 Jan-Mar;60(1):26-33
pubmed: 26911214
BMC Nutr. 2015 Oct 14;1:22
pubmed: 26918196
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Saudi J Gastroenterol. 2016 May-Jun;22(3):192-7
pubmed: 27184636
Indian J Med Res. 2016 Sep;144(3):460-471
pubmed: 28139545
Hepatol Int. 2017 May;11(3):286-291
pubmed: 28425016
Dig Liver Dis. 2017 Oct;49(10):1133-1138
pubmed: 28572039